Facts for Prelims (FFP)
Source: Reuters
Context: The U.S. Food and Drug Administration (FDA) has granted approval for two gene therapies for sickle cell disease.
- Developed by Vertex Pharmaceuticals and CRISPR Therapeutics, Casgevy, and bluebird bio’s Lyfgenia have been approved for individuals aged 12 years and older.
- One of the approved therapies, Casgevy, is based on the CRISPR gene editing technology, making it the first treatment in the U.S. to utilize the Nobel Prize-winning CRISPR gene editing technology.
Sickle cell disease is an inherited blood disorder causing flawed, sickle-shaped hemoglobin, affecting the oxygen-carrying ability of red blood cells.Top of Form
